Copyright
©The Author(s) 2023.
World J Clin Cases. Aug 26, 2023; 11(24): 5643-5652
Published online Aug 26, 2023. doi: 10.12998/wjcc.v11.i24.5643
Published online Aug 26, 2023. doi: 10.12998/wjcc.v11.i24.5643
Prognostic factor | PFS | OS | ||
HR (95%CI) | P value | HR (95%CI) | P value | |
Age (yr) | 1.051 (1.031-1.071) | ≤ 0.001 | 1.034 (1.012-1.055) | 0.002 |
Gender | 1.265 (0.828-1.931) | 0.277 | 1.412 (0.926-2.152) | 0.109 |
Classification | 1.037 (0.949-1.132) | 1.037 | 1.093 (0.999-1.196) | 0.053 |
ISS stage | 1.718 (1.247-2.366) | 0.001 | 2.093 (1.520-2.883) | ≤ 0.001 |
DS stage | 2.094 (1.082-4.054) | 0.028 | 1.982 (1.015-3.869) | 0.045 |
GPT | 1.011 (1.002-1.021) | 0.019 | 1.009 (0.999-1.019) | 0.082 |
GOT | 1.022 (1.011-1.033) | ≤ 0.001 | 1.025 (1.013-1.038) | ≤ 0.001 |
CRP | 1.002 (0.996-1.007) | 0.593 | 1.002 (0.996-1.008) | 0.491 |
A/G | 1.041 (0.698-1.553) | 0.844 | 1.149 (0.754-1.751) | 0.518 |
LDH | 1.003 (1.001-1.004) | ≤ 0.001 | 1.003 (1.002-1.005) | ≤ 0.001 |
t(6;14) | 1.021 (0.319-3.266) | 0.972 | 1.285 (0.399-4.134) | 0.674 |
t(11;14) | 1.149 (0.281-4.708) | 0.847 | 1.188 (0.290-4.871) | 0.811 |
Platelet count | 9.604 (4.965-18.578) | ≤ 0.001 | 8.437 (4.528-15.721) | ≤ 0.001 |
Herpes | 0.821 (0.451-1.495) | 0.52 | 0.908 (0.498-1.653) | 0.751 |
Chemotherapy regimen | 1.005 (0.856-1.180) | 0.952 | 0.949 (0.795-1.133) | 0.564 |
Autotransplantation | 0.339 (0.137-0.842) | 0.020 | 0.347 (0.140-0.860) | 0.022 |
TC | 0.773 (0.631-0.947) | 0.013 | 0.757 (0.617-0.927) | 0.007 |
TG | 0.861 (0.666-1.114) | 0.255 | 0.846 (0.642-1.113) | 0.232 |
P | 1.143 (0.953-1.370) | 0.15 | 1.113 (0.934-1.325) | 0.232 |
C1 reduction rate | 0.412 (0.325-0.521) | ≤ 0.001 | 0.438 (0.346-0.554) | ≤ 0.001 |
C2 reduction rate | 0.412 (0.325-0.523) | ≤ 0.001 | 0.441 (0.351-0.553) | ≤ 0.001 |
C3 reduction rate | 0.390 (0.303-0.501) | ≤ 0.001 | 0.377 (0.290-0.490) | ≤ 0.001 |
C4 reduction rate | 0.358 (0.283-0.455) | ≤ 0.001 | 0.345 (0.267-0.445) | ≤ 0.001 |
- Citation: Liu M, Zhang JY. Reduction rate of monoclonal protein as a useful prognostic factor in standard-risk group of newly diagnosed multiple myeloma. World J Clin Cases 2023; 11(24): 5643-5652
- URL: https://www.wjgnet.com/2307-8960/full/v11/i24/5643.htm
- DOI: https://dx.doi.org/10.12998/wjcc.v11.i24.5643